Patents by Inventor Thomas D. Chittenden

Thomas D. Chittenden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090081705
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-xL, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Application
    Filed: March 11, 2008
    Publication date: March 26, 2009
    Inventors: Thomas D. CHITTENDEN, Robert J. LUTZ
  • Patent number: 7358088
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-xL, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: April 15, 2008
    Assignee: ImmunoGen, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz
  • Patent number: 7097982
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-xL, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: August 29, 2006
    Assignee: ImmunoGen, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz
  • Publication number: 20040054129
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-xL, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Application
    Filed: April 10, 2001
    Publication date: March 18, 2004
    Applicant: Apoptosis Technology, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz
  • Patent number: 6221615
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain”, which is essential both to Bak's interaction with Bcl-xL, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: April 24, 2001
    Assignee: Apoptosis Technology, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz
  • Patent number: 5863795
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the "GD domain," which is essential both to Bak's interaction with Bcl-x.sub.L, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: January 26, 1999
    Assignee: Apoptosis Technology, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz
  • Patent number: 5672686
    Abstract: The present invention is directed to an isolated Bcl-Y protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the Bcl-Y protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect Bcl-Y in biological specimens, including, for example, human tissue samples. The present invention is further directed to methods of treating degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death. The present invention is further directed to methods for diagnosing degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death, as well as methods for monitoring the progress of such degenerative disorders.
    Type: Grant
    Filed: October 11, 1994
    Date of Patent: September 30, 1997
    Assignee: ImmunoGen, Inc.
    Inventor: Thomas D. Chittenden
  • Patent number: 5656725
    Abstract: The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the "GD domain," which is essential both to Bak's interaction with Bcl-x.sub.L, and to Bak's cell killing function. Methods of identifying agonists or antagonists of GD domain function are provided. The GD domain is responsible for mediating key protein/protein interactions of significance to the actions of multiple cell death regulatory molecules.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: August 12, 1997
    Assignee: Apoptosis Technology, Inc.
    Inventors: Thomas D. Chittenden, Robert J. Lutz